- Home
- OSTX
as 11-15-2024 4:00pm EST
Stocks
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 86.5M | IPO Year: | 2024 |
| Target Price: | $21.00 | AVG Volume (30 days): | 19.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $4.90 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 9900.00% |
Latest OS THERAPIES INCORPORATED News
OSTX Breaking Stock News: Dive into OSTX Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
Business Wire
14 days ago
OS Therapies to Present at The Spartan Capital Investor Conference
Business Wire
18 days ago
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
Business Wire
20 days ago
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
Business Wire
24 days ago
OS Therapies to Present at the LD Micro Main Event XVII
Business Wire
a month ago
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Business Wire
a month ago
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
Business Wire
2 months ago
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
Compare OSTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OSTX OS THERAPIES INCORPORATED - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.